FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Brann

Research Profile

Chemicals & Drugs

Living Beings

Mouse
Rats

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Andria L Del Tredici; Kim E Vanover; Anne E Knapp; Sine M Bertozzi; Norman R Nash; Ethan S Burstein; Jelveh Lameh; Erika A Currier; Robert E Davis; Mark R Brann; Nina Mohell; Roger Olsson; Fabrice Piu
Identification of novel selective V2 receptor non-peptide agonists.
Luis R Gardell; Lene Hyldtoft; Andria L Del Tredici; Carsten B Andersen; Luke C Fairbairn; Birgitte W Lund; Magnus Gustafsson; Mark R Brann; Roger Olsson; Fabrice Piu
Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist.
Fabrice Piu; Cindy Cheevers; Lene Hyldtoft; Luis R Gardell; Andria L Del Tredici; Carsten B Andersen; Luke C Fairbairn; Birgitte W Lund; Magnus Gustafsson; Hans H Schiffer; John E Donello; Roger Olsson; Daniel W Gil; Mark R Brann
Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Brann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Andria L Del Tredici; Kim E Vanover; Anne E Knapp; Sine M Bertozzi; Norman R Nash; Ethan S Burstein; Jelveh Lameh; Erika A Currier; Robert E Davis; Mark R Brann; Nina Mohell; Roger Olsson; Fabrice Piu
Identification of novel selective V2 receptor non-peptide agonists.
Biochemical pharmacology 2008;76(9):1134-41.
2008: Luis R Gardell; Lene Hyldtoft; Andria L Del Tredici; Carsten B Andersen; Luke C Fairbairn; Birgitte W Lund; Magnus Gustafsson; Mark R Brann; Roger Olsson; Fabrice Piu
Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist.
European journal of pharmacology 2008;592(1-3):158-9.
2008: Fabrice Piu; Cindy Cheevers; Lene Hyldtoft; Luis R Gardell; Andria L Del Tredici; Carsten B Andersen; Luke C Fairbairn; Birgitte W Lund; Magnus Gustafsson; Hans H Schiffer; John E Donello; Roger Olsson; Daniel W Gil; Mark R Brann
Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.
European journal of pharmacology 2008;590(1-3):423-9.
2008: Anna-Lena Nordstrom; Mattias Mansson; Hristina Jovanovic; Per Karlsson; Christer Halldin; Lars Farde; Kimberly E Vanover; Uli Hacksell; Mark R Brann; Robert E Davis; David M Weiner
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2008;11(2):163-71.
2008: Remko A Bakker; Aldo Jongejan; Kamonchanok Sansuk; Uli Hacksell; Henk Timmerman; Mark R Brann; David M Weiner; Leonardo Pardo; Rob Leurs
Constitutively active mutants of the histamine H1 receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation of class A G protein-coupled receptors.
Molecular pharmacology 2008;73(1):94-103.
2007: Philip K Tan; Jean Wang; Pey-Lih H Littler; Kenneth K Wong; Timothy A Sweetnam; William Keefe; Norman R Nash; Esther C Reding; Fabrice Piu; Mark R Brann; Hans H Schiffer
Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
Molecular pharmacology 2007;72(6):1440-6.
2007: Luis R Gardell; Kimberly E Vanover; Linda Pounds; Robert W Johnson; Richard Barido; Gary T Anderson; isaac veinbergs; Agnete Dyssegaard; Per Brunmark; Ali Tabatabaei; Robert E Davis; Mark R Brann; Uli Hacksell; Douglas W Bonhaus
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
The Journal of pharmacology and experimental therapeutics 2007;322(2):862-70.
2007: Jian-Nong Ma; Hans H Schiffer; Anne E Knapp; Jean Wang; Kenneth K Wong; Erika A Currier; Michelle Owens; Norman R Nash; Luis R Gardell; Mark R Brann; Roger Olsson; Ethan S Burstein
Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists.
Molecular pharmacology 2007;72(2):380-6.
2007: Remko A Bakker; M W Nicholas; T T Smith; Ethan S Burstein; Uli Hacksell; Henk Timmerman; Rob Leurs; Mark R Brann; David M Weiner
In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.
The Journal of pharmacology and experimental therapeutics 2007;322(1):172-9.
2007: Hans H Schiffer; Esther C Reding; Stephen R Fuhs; Qing Lu; Fabrice Piu; Steven Wong; Pey-Lih H Littler; David M Weiner; William Keefe; Phil K Tan; Norman R Nash; Anne E Knapp; Roger Olsson; Mark R Brann
Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.
Molecular pharmacology 2007;71(2):508-18.
2006: Tracy A Spalding; Jian-Nong Ma; Thomas R Ott; Mikael Friberg; Abhishek Bajpai; Stefania Risso Bradley; Robert E Davis; Mark R Brann; Ethan S Burstein
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.
Molecular pharmacology 2006;70(6):1974-83.
2006: Kimberly E Vanover; David M Weiner; Malath Makhay; isaac veinbergs; Luis R Gardell; Jelveh Lameh; Andria L Del Tredici; Fabrice Piu; Hans H Schiffer; Thomas R Ott; Ethan S Burstein; Allan K Uldam; Mikkel B Thygesen; Nathalie Schlienger; Carl Magnus Andersson; Thomas Y Son; Scott C Harvey; Susan B Powell; Mark A Geyer; Bo-Ragnar Tolf; Mark R Brann; Robert E Davis
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
The Journal of pharmacology and experimental therapeutics 2006;317(2):910-8.
2006: Ethan S Burstein; Fabrice Piu; Jian-Nong Ma; Jacques T Weissman; Erika A Currier; Norman R Nash; David M Weiner; Tracy A Spalding; Hans H Schiffer; Andria L Del Tredici; Mark R Brann
Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout.
Current pharmaceutical design 2006;12(14):1717-29.
2006: Ethan S Burstein; Thomas R Ott; Michele Feddock; Jian-Nong Ma; Steve Fuhs; Steven Wong; Hans H Schiffer; Mark R Brann; Norman R Nash
Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors.
British journal of pharmacology 2006;147(1):73-82.
2005: Fabrice Piu; Natalie K Gauthier; Roger Olsson; Erika A Currier; Birgitte W Lund; Glenn E Croston; Uli Hacksell; Mark R Brann
Identification of novel subtype selective RAR agonists.
Biochemical pharmacology 2005;71(1-2):156-62.
2005: Birgitte W Lund; Fabrice Piu; Natalie K Gauthier; Anne Eeg; Erika A Currier; Vladimir Sherbukhin; Mark R Brann; Uli Hacksell; Roger Olsson
Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
Journal of medicinal chemistry 2005;48(24):7517-9.
2005: Ethan S Burstein; J Ma; Steven Wong; Y Gao; E Pham; Anne E Knapp; Norman R Nash; Roger Olsson; Robert E Davis; Uli Hacksell; David M Weiner; Mark R Brann
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
The Journal of pharmacology and experimental therapeutics 2005;315(3):1278-87.
2004: David M Weiner; Herbert Y Meltzer; isaac veinbergs; E M Donohue; Tracy A Spalding; T T Smith; Nina Mohell; Scott C Harvey; Jelveh Lameh; Norman R Nash; Kimberly E Vanover; Roger Olsson; K Jayathilake; Michael K Lee; Allan Levey; Uli Hacksell; Ethan S Burstein; Robert E Davis; Mark R Brann
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
Psychopharmacology 2004;177(1-2):207-16.
2004: Kimberly E Vanover; Scott C Harvey; Thomas Son; Stefania Risso Bradley; Henriette Kold; Malath Makhay; isaac veinbergs; Tracy A Spalding; David M Weiner; Carl Magnus Andersson; Bo-Ragnar Tolf; Mark R Brann; Uli Hacksell; Robert E Davis
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
The Journal of pharmacology and experimental therapeutics 2004;310(3):943-51.
2004: Jian-Nong Ma; Erika A Currier; Anthony Essex; Michele Feddock; Tracy A Spalding; Norman R Nash; Mark R Brann; Ethan S Burstein
Discovery of novel peptide/receptor interactions: identification of PHM-27 as a potent agonist of the human calcitonin receptor.
Biochemical pharmacology 2004;67(7):1279-84.
2004: Jakob Lerche Hansen; Stig Haunsø; Mark R Brann; Søren P Sheikh; David M Weiner
Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor.
Molecular pharmacology 2004;65(3):770-7.
2004: Remko A Bakker; David M Weiner; Antonius Marinus ter Laak; T Beuming; Obbe P Zuiderveld; M Edelbroek; Uli Hacksell; Henk Timmerman; Mark R Brann; Rob Leurs
8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist.
Molecular pharmacology 2004;65(3):538-49.
2004: Andria L Del Tredici; Hans H Schiffer; Ethan S Burstein; Jelveh Lameh; Nina Mohell; Uli Hacksell; Mark R Brann; David M Weiner
Pharmacology of polymorphic variants of the human 5-HT1A receptor.
Biochemical pharmacology 2004;67(3):479-90.
2004: David M Weiner; Matilda W Goodman; Tonya M Colpitts; Michele Feddock; Kate L Duggento; Norman R Nash; Allan Levey; Mark R Brann
Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2004;4(2):119-28.
2003: David M Weiner; Kimberly E Vanover; Mark R Brann; Herbert Y Meltzer; Robert E Davis
Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics.
Current opinion in investigational drugs (London, England : 2000) 2003;4(7):815-9.
2003: Andria Lee; B K Rana; Hans H Schiffer; N J Schork; Mark R Brann; P A Insel; David M Weiner
Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family.
Genomics 2003;81(3):245-8.
2002: Glenn E Croston; Roger Olsson; Erika A Currier; Ethan S Burstein; David Weiner; Norman R Nash; Daniel Severance; Stig G Allenmark; Linda Thunberg; Jian-Nong Ma; Nina Mohell; Brian O'Dowd; Mark R Brann; Uli Hacksell
Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).
Journal of medicinal chemistry 2002;45(23):4950-3.
2002: P Wellendorph; M W Goodman; Ethan S Burstein; Norman R Nash; Mark R Brann; David M Weiner
Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H(3) receptor.
Neuropharmacology 2002;42(7):929-40.
2002: Tracy A Spalding; Carol Trotter; Niels Skjaerbaek; Terri L Messier; Erika A Currier; Ethan S Burstein; Donghui Li; Uli Hacksell; Mark R Brann
Discovery of an ectopic activation site on the M(1) muscarinic receptor.
Molecular pharmacology 2002;61(6):1297-302.
2002: Uli Hacksell; Norman Nash; Ethan S Burstein; Fabrice Piu; Glenn Croston; Mark R Brann
Chemical genomics: massively parallel technologies for rapid lead identification and target validation.
Cytotechnology 2002;38(1-3):3-10.
2001: David M Weiner; Ethan S Burstein; Norman R Nash; Glenn E Croston; Erika A Currier; Kimberly E Vanover; Scott C Harvey; E Donohue; H C Hansen; Carl Magnus Andersson; Tracy A Spalding; D F Gibson; K Krebs-Thomson; S B Powell; Mark A Geyer; Uli Hacksell; Mark R Brann
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
The Journal of pharmacology and experimental therapeutics 2001;299(1):268-76.
2001: Daniel W Gil; Tracy A Spalding; Alexander B Kharlamb; N Skjaerbaek; A Uldam; C Trotter; D Li; Elizabeth WoldeMussie; Larry Wheeler; Mark R Brann
Exploring the potential for subtype-selective muscarinic agonists in glaucoma.
Life sciences 2001;68(22-23):2601-4.
2000: Anders A Jensen; Tracy A Spalding; Ethan S Burstein; PO Sheppard; PJ O'Hara; Mark R Brann; Povl Krogsgaard-Larsen; Hans Bräuner-Osborne
Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor. Constitutive activity and inverse agonism in a family C G-protein-coupled receptor.
The Journal of biological chemistry 2000;275(38):29547-55.
1998: Ethan S Burstein; D J Hesterberg; J Silvio Gutkind; Mark R Brann; Erika A Currier; T L Messier
The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors.
Oncogene 1998;17(12):1617-23.
1998: Ethan S Burstein; Tracy A Spalding; Mark R Brann
The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling.
The Journal of biological chemistry 1998;273(38):24322-7.
1998: Tracy A Spalding; Ethan S Burstein; S C Henderson; K R Ducote; Mark R Brann
Identification of a ligand-dependent switch within a muscarinic receptor.
The Journal of biological chemistry 1998;273(34):21563-8.
1998: Ethan S Burstein; Tracy A Spalding; Mark R Brann
Structure/function relationships of a G-protein coupling pocket formed by the third intracellular loop of the m5 muscarinic receptor.
Biochemistry 1998;37(12):4052-8.
1997: Tracy A Spalding; Ethan S Burstein; J W Wells; Mark R Brann
Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6.
Biochemistry 1997;36(33):10109-16.
1997: Ethan S Burstein; Tracy A Spalding; Mark R Brann
Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins.
Molecular pharmacology 1997;51(2):312-9.
1997: Ethan S Burstein; H Bräuner-Osborne; Tracy A Spalding; Bruce R Conklin; Mark R Brann
Interactions of muscarinic receptors with the heterotrimeric G proteins Gq and G12: transduction of proliferative signals.
Journal of neurochemistry 1997;68(2):525-33.
1997: Ethan S Burstein; Tracy A Spalding; Mark R Brann
Use of random-saturation mutagenesis to study receptor-G protein coupling.
Methods in molecular biology (Clifton, N.J.) 1997;83():143-57.
1996: Hans Bräuner-Osborne; Bjarke Ebert; Mark R Brann; Erik Falch; Povl Krogsgaard-Larsen
Functional partial agonism at cloned human muscarinic acetylcholine receptors.
European journal of pharmacology 1996;313(1-2):145-50.
1996: Gordon Y K Ng; Brian F O'Dowd; S P Lee; H T Chung; Mark R Brann; Philip Seeman; Susan R George
Dopamine D2 receptor dimers and receptor-blocking peptides.
Biochemical and biophysical research communications 1996;227(1):200-4.
1996: S Lam; Y Shen; Tuan V Nguyen; T L Messier; Mark R Brann; D Comings; Susan R George; Brian F O'Dowd
A serotonin receptor gene (5HT1A) variant found in a Tourette's syndrome patient.
Biochemical and biophysical research communications 1996;219(3):853-8.
1996: Ethan S Burstein; Tracy A Spalding; Mark R Brann
Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains.
Biochemical pharmacology 1996;51(4):539-44.
1996: D Hill-Eubanks; Ethan S Burstein; Tracy A Spalding; Hans Bräuner-Osborne; Mark R Brann
Structure of a G-protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis.
The Journal of biological chemistry 1996;271(6):3058-65.
1996: Ethan S Burstein; Tracy A Spalding; Mark R Brann
Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop.
The Journal of biological chemistry 1996;271(6):2882-5.
1996: Hans Bräuner-Osborne; Mark R Brann
Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells.
European journal of pharmacology 1996;295(1):93-102.
1995: Tracy A Spalding; Ethan S Burstein; H Brauner-Osborne; D Hill-Eubanks; Mark R Brann
Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis.
The Journal of pharmacology and experimental therapeutics 1995;275(3):1274-9.
1995: Hans Bräuner-Osborne; Bjarke Ebert; Mark R Brann; Erik Falch; Povl Krogsgaard-Larsen
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
Journal of medicinal chemistry 1995;38(12):2188-95.
1995: Ethan S Burstein; Tracy A Spalding; H Braüner-Osborne; Mark R Brann
Constitutive activation of muscarinic receptors by the G-protein Gq.
FEBS letters 1995;363(3):261-3.
1995: Ethan S Burstein; Tracy A Spalding; D Hill-Eubanks; Mark R Brann
Structure-function of muscarinic receptor coupling to G proteins. Random saturation mutagenesis identifies a critical determinant of receptor affinity for G proteins.
The Journal of biological chemistry 1995;270(7):3141-6.
1994: Gordon Y K Ng; Brian F O'Dowd; M Caron; M Dennis; Mark R Brann; Susan R George
Phosphorylation and palmitoylation of the human D2L dopamine receptor in Sf9 cells.
Journal of neurochemistry 1994;63(5):1589-95.
1993: Mark R Brann; H B Jørgensen; Ethan S Burstein; Tracy A Spalding; J Ellis; S V Penelope Jones; D Hill-Eubanks
Studies of the pharmacology, localization, and structure of muscarinic acetylcholine receptors.
Annals of the New York Academy of Sciences 1993;707():225-36.
1993: Allan Levey; Steven M Hersch; David B Rye; Roger K Sunahara; Hyman B Niznik; C A Kitt; Donald L Price; R Maggio; Mark R Brann; Brian Ciliax
Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(19):8861-5.
1993: J Ellis; M Seidenberg; Mark R Brann
Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions.
Molecular pharmacology 1993;44(3):583-8.
1993: E V Stephens; G Kalinec; Mark R Brann; J Silvio Gutkind
Transforming G protein-coupled receptors transduce potent mitogenic signals in NIH 3T3 cells independent on cAMP inhibition or conventional protein kinase C.
Oncogene 1993;8(1):19-26.
1993: Mark R Brann; J Ellis; H Jørgensen; D Hill-Eubanks; S V Penelope Jones
Muscarinic acetylcholine receptor subtypes: localization and structure/function.
Progress in brain research 1993;98():121-7.
1992: J Wess; D Gdula; Mark R Brann
Structural basis of the subtype selectivity of muscarinic antagonists: a study with chimeric m2/m5 muscarinic receptors.
Molecular pharmacology 1992;41(2):369-74.
1991: J Wess; D Gdula; Mark R Brann
Site-directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding.
The EMBO journal 1991;10(12):3729-34.
1991: J Ellis; J Huyler; Mark R Brann
Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes.
Biochemical pharmacology 1991;42(10):1927-32.
1991: Allan Levey; C A Kitt; William F Simonds; Donald L Price; Mark R Brann
Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1991;11(10):3218-26.
1991: F Dörje; Allan Levey; Mark R Brann
Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues.
Molecular pharmacology 1991;40(4):459-62.
1991: S V Penelope Jones; C J Heilman; Mark R Brann
Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells.
Molecular pharmacology 1991;40(2):242-7.
1991: J Silvio Gutkind; Elizabeth A Novotny; Mark R Brann; K C Robbins
Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(11):4703-7.
1991: D M Weiner; Allan Levey; Roger K Sunahara; Hyman B Niznik; Brian F O'Dowd; Philip Seeman; Mark R Brann
D1 and D2 dopamine receptor mRNA in rat brain.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(5):1859-63.
1991: F Dörje; J Wess; Günter Lambrecht; R Tacke; Ernst Mutschler; Mark R Brann
Antagonist binding profiles of five cloned human muscarinic receptor subtypes.
The Journal of pharmacology and experimental therapeutics 1991;256(2):727-33.
1991: J Wess; Günter Lambrecht; Ernst Mutschler; Mark R Brann; F Dörje
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
British journal of pharmacology 1991;102(1):246-50.
1990: J Wess; T I Bonner; Mark R Brann
Chimeric m2/m3 muscarinic receptors: role of carboxyl terminal receptor domains in selectivity of ligand binding and coupling to phosphoinositide hydrolysis.
Molecular pharmacology 1990;38(6):872-7.
1990: Allan Levey; T M Stormann; Mark R Brann
Bacterial expression of human muscarinic receptor fusion proteins and generation of subtype-specific antisera.
FEBS letters 1990;275(1-2):65-9.
1990: J Wess; T I Bonner; F Dörje; Mark R Brann
Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers.
Molecular pharmacology 1990;38(4):517-23.
1990: Roger K Sunahara; Hyman B Niznik; D M Weiner; T M Stormann; Mark R Brann; James L Kennedy; Joel Gelernter; Richard Rozmahel; Y L Yang; Y Israel
Human dopamine D1 receptor encoded by an intronless gene on chromosome 5.
Nature 1990;347(6288):80-3.
1990: D M Weiner; Allan Levey; Mark R Brann
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(18):7050-4.
1990: S V Penelope Jones; Jeffery L Barker; Miriam B Goodman; Mark R Brann
Inositol trisphosphate mediates cloned muscarinic receptor-activated conductances in transfected mouse fibroblast A9 L cells.
The Journal of physiology 1990;421():499-519.
1990: Mark R Brann; J Wess; S V Penelope Jones
Molecular genetics of signal transduction by muscarinic acetylcholine receptors.
Society of General Physiologists series 1990;45():105-15.
1990: T M Stormann; D C Gdula; D M Weiner; Mark R Brann
Molecular cloning and expression of a dopamine D2 receptor from human retina.
Molecular pharmacology 1990;37(1):1-6.
1990: Teresa L Z Jones; William F Simonds; J J Merendino; Mark R Brann; Allen Spiegel
Myristoylation of an inhibitory GTP-binding protein alpha subunit is essential for its membrane attachment.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(2):568-72.
1989: J Wess; Mark R Brann; Tom Bonner
Identification of a small intracellular region of the muscarinic m3 receptor as a determinant of selective coupling to PI turnover.
FEBS letters 1989;258(1):133-6.
1989: William F Simonds; R M Collins; Allen Spiegel; Mark R Brann
Membrane attachment of recombinant G-protein alpha-subunits in excess of beta gamma subunits in a eukaryotic expression system.
Biochemical and biophysical research communications 1989;164(1):46-53.
1989: D M Weiner; Mark R Brann
The distribution of a dopamine D2 receptor mRNA in rat brain.
FEBS letters 1989;253(1-2):207-13.
1989: N J Buckley; Tom Bonner; C M Buckley; Mark R Brann
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
Molecular pharmacology 1989;35(4):469-76.
1988: N J Buckley; Tom Bonner; Mark R Brann
Localization of a family of muscarinic receptor mRNAs in rat brain.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1988;8(12):4646-52.
1988: Bruce R Conklin; Mark R Brann; N J Buckley; A L Ma; Tom Bonner; Julius Axelrod
Stimulation of arachidonic acid release and inhibition of mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(22):8698-702.
1988: S V Penelope Jones; Jeffery L Barker; N J Buckley; Tom Bonner; R M Collins; Mark R Brann
Cloned muscarinic receptor subtypes expressed in A9 L cells differ in their coupling to electrical responses.
Molecular pharmacology 1988;34(4):421-6.
1988: Tom Bonner; A C Young; Mark R Brann; N J Buckley
Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes.
Neuron 1988;1(5):403-10.
1988: S V Penelope Jones; Jeffery L Barker; Tom Bonner; N J Buckley; Mark R Brann
Electrophysiological characterization of cloned m1 muscarinic receptors expressed in A9 L cells.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(11):4056-60.
1988: Mark R Brann; N J Buckley; Tom Bonner
The striatum and cerebral cortex express different muscarinic receptor mRNAs.
FEBS letters 1988;230(1-2):90-4.
1987: Mark R Brann; N J Buckley; S V Penelope Jones; Tom Bonner
Expression of a cloned muscarinic receptor in A9 L cells.
Molecular pharmacology 1987;32(4):450-5.
1987: Mark R Brann; R M Collins; Allen Spiegel
Localization of mRNAs encoding the alpha-subunits of signal-transducing G-proteins within rat brain and among peripheral tissues.
FEBS letters 1987;222(1):191-8.